|
David Lucking has been a director of our company since June 2002. Since March 2003, he has been employed by ACCU-BREAK Pharmaceuticals Inc. (f/k/a SoLapharm, Inc.), a development-stage pharmaceutical firm, as Senior Executive Vice President and Chief Operating Officer. Previously, Mr. Lucking held senior management positions at Noven Pharmaceuticals, Inc. from its inception in 1987 until March 2003, when he joined SoLapharm. At Noven, he served as Executive Director of Regulatory Affairs and was extensively involved in conducting preclinical and clinical trials, coordinating with the FDA and European pharmaceutical regulatory agencies and participating in creating strategic plans relating to developing pharmaceutical projects from concept to FDA approval. | 